-
公开(公告)号：US20220387355A1
公开(公告)日：2022-12-08
申请号：US17883902
申请日：2022-08-09
IPC分类号： A61K31/135 , A61K9/28 , A61P25/22 , A61K45/06 , A61K9/20
摘要： The disclosure provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
-
公开(公告)号：US20220347104A1
公开(公告)日：2022-11-03
申请号：US17851590
申请日：2022-06-28
IPC分类号： A61K9/28 , A61K31/135 , A61K9/20 , A61P25/22
摘要： The invention provides an oral extended release formulation for the treatment of treatment-resistant depression, treatment-resistant anxiety, and phobia.
-
公开(公告)号：US11471415B2
公开(公告)日：2022-10-18
申请号：US16754389
申请日：2018-10-10
摘要： The invention provides an oral extended release formulation for the treatment of treatment-resistant depression, treatment-resistant anxiety, and phobia.
-
公开(公告)号：US20210213016A1
公开(公告)日：2021-07-15
申请号：US17055067
申请日：2019-05-23
发明人： Ian Hampson , Lynne Hampson
IPC分类号： A61K31/513 , A61K31/427 , A61K9/00 , A61K9/06 , A61P35/00
摘要： The present invention concerns pharmaceutical compositions formulated for dermal application comprising a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir: ritonavir is between 9:1 and 18:1. Such compositions are useful for treating, or preventing, skin cancers and premalignant dermal conditions.
-
公开(公告)号：US10744094B2
公开(公告)日：2020-08-18
申请号：US16367855
申请日：2019-03-28
IPC分类号： A61K9/28 , A61K9/00 , A61K9/20 , A61K45/06 , A61K31/135
摘要： The invention provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
-
公开(公告)号：US20200000731A1
公开(公告)日：2020-01-02
申请号：US16565648
申请日：2019-09-10
IPC分类号： A61K9/28 , A61K9/00 , A61K9/20 , A61K45/06 , A61K31/135
摘要： The invention provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
-
公开(公告)号：US12083120B2
公开(公告)日：2024-09-10
申请号：US17055067
申请日：2019-05-23
发明人： Ian Hampson , Lynne Hampson
IPC分类号： A61K31/513 , A61K9/00 , A61K9/06 , A61K31/427 , A61K35/00 , A61P35/00
CPC分类号： A61K31/513 , A61K9/0014 , A61K9/06 , A61K31/427 , A61P35/00
摘要： The present invention concerns pharmaceutical compositions formulated for dermal application comprising a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir:ritonavir is between 9:1 and 18:1. Such compositions are useful for treating, or preventing, skin cancers and premalignant dermal conditions.
-
公开(公告)号：US20240189259A2
公开(公告)日：2024-06-13
申请号：US18028202
申请日：2021-09-22
发明人： Paul Glue , Natalie Medlicott , Peter Surman , Yuefeng Long
IPC分类号： A61K31/135 , A61K9/00 , A61K9/28 , A61P25/24
CPC分类号： A61K31/135 , A61K9/0053 , A61K9/2853 , A61P25/24
摘要： The disclosure provides a dosing regimen utilizing an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
-
公开(公告)号：US10441544B2
公开(公告)日：2019-10-15
申请号：US15728695
申请日：2017-10-10
IPC分类号： A61K9/28 , A61K9/00 , A61K9/20 , A61K45/06 , A61K31/135
摘要： The invention provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
-
公开(公告)号：US20190105276A1
公开(公告)日：2019-04-11
申请号：US15728695
申请日：2017-10-10
IPC分类号： A61K9/28 , A61K9/00 , A61K9/20 , A61K31/135 , A61K45/06
CPC分类号： A61K9/28 , A61K9/0053 , A61K9/2031 , A61K9/2813 , A61K9/2853 , A61K9/2866 , A61K31/135 , A61K45/06
摘要： The invention provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.022 秒)
